BNGO Bionano Genomics, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1411690 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY22.0%
TTM EPS YoY84.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin48.0%
Operating margin-97.1%
Net margin-96.9%
FCF margin—
EBITDA margin-76.0%
Returns
ROE-77.2%
ROA-48.0%
ROIC (approx.)-67.6%
Asset turnover0.50x
Leverage & solvency
Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-17.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.28M | $8.17M | $6.69M | $7.95M | $7.37M | $6.73M | $6.46M | $8.16M |
| Cost of revenue | $4.33M | $3.86M | $3.44M | $4.55M | $4.00M | $3.26M | $3.52M | $4.75M |
| Gross profit | $3.95M | $4.31M | $3.25M | $3.40M | $3.37M | $3.48M | $2.94M | $3.42M |
| R&D expense | $3.04M | $2.99M | $3.14M | $3.23M | $2.84M | $2.93M | $2.37M | $3.47M |
| SG&A expense | $7.44M | $8.54M | $8.01M | $8.71M | $9.06M | $8.35M | $9.03M | $11.75M |
| Operating income | -$6.54M | -$7.22M | -$7.90M | -$8.54M | -$8.54M | -$7.80M | -$8.46M | -$11.94M |
| Pretax income | -$6.45M | -$7.42M | -$8.29M | -$7.90M | -$8.49M | -$6.85M | -$3.10M | -$20.12M |
| Income tax | $8,000 | $7,000 | $10,000 | $35,000 | $14,000 | $10,000 | $7,000 | $1,000 |
| Net income | -$6.45M | -$7.42M | -$8.30M | -$7.93M | -$8.50M | -$6.86M | -$3.10M | -$20.12M |
| EBITDA | -$5.64M | -$6.22M | -$5.59M | -$6.20M | -$7.54M | -$6.80M | -$6.03M | -$9.54M |
| EPS (basic) | -0.54 | -0.64 | -0.76 | — | -1.59 | -1.99 | -1.15 | — |
| EPS (diluted) | -0.54 | -0.64 | -0.76 | — | -1.59 | -1.99 | -1.15 | — |
| Weighted avg. shares (diluted) | 11.99M | 11.55M | 10.98M | — | 5.34M | 3.44M | 2.69M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.36M | $3.73M | $3.42M | $2.99M | $3.06M | $3.56M | $3.62M | $9.17M |
| Short-term investments | $3.81M | $6.19M | $10.98M | $16.28M | $18.52M | $12.88M | $14.61M | $302,000 |
| Receivables | $5.85M | $4.37M | $4.13M | $5.20M | $4.53M | $3.49M | $3.35M | $4.75M |
| Inventory | $8.70M | $7.01M | $7.69M | $7.83M | $8.42M | $10.31M | $11.42M | $13.28M |
| Current assets | $25.52M | $24.88M | $38.98M | $45.39M | $48.80M | $42.66M | $44.93M | $39.49M |
| PP&E, net | $12.23M | $13.02M | $14.04M | $14.85M | $16.17M | $17.26M | $18.34M | $19.22M |
| Intangibles | $325,000 | $1.67M | $3.00M | $4.34M | $5.68M | $7.03M | $8.37M | $9.71M |
| Total assets | $46.29M | $47.59M | $64.80M | $73.58M | $79.06M | $76.01M | $78.41M | $76.67M |
| Current liabilities | $12.31M | $10.04M | $21.23M | $22.94M | $22.98M | $24.18M | $26.41M | $37.34M |
| Total liabilities | $18.08M | $15.98M | $27.34M | $29.16M | $29.26M | $30.64M | $30.23M | $41.30M |
| Shareholders' equity | $28.21M | $31.61M | $37.46M | $44.42M | $49.80M | $45.37M | $48.19M | $35.38M |
| Shares outstanding | 13.51M | 11.78M | 11.28M | 10.74M | 9.73M | 3.91M | 3.10M | 1.87M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.52M | -$4.67M | -$5.72M | -$4.17M | -$5.92M | -$3.49M | -$2.76M | -$6.50M |
| Investing cash flow | $2.41M | $13.68M | $5.46M | $4.01M | -$4.67M | $1.98M | -$14.07M | $3.00M |
| Financing cash flow | $2.74M | -$9.69M | $657,000 | $1.60M | $10.08M | $1.47M | $10.89M | $3.89M |
| Depreciation & amortization | $900,000 | $1.00M | $2.31M | $2.34M | $1.00M | $1.00M | $2.43M | $2.40M |
| Stock-based compensation | $299,000 | $970,000 | $670,000 | $926,000 | $941,000 | $1.08M | $1.59M | $1.94M |
Free plan shows the latest 8 periods; Pro shows all 40 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.